论文部分内容阅读
目的评价头孢哌酮/舒巴坦钠(拉菲)的安全性及临床疗效。方法182例感染患者被入选随机对照及开放实验,与头孢哌酮舒巴坦钠(舒巴酮)比较。用药方法:两药均为(1.5~3.0g/次12h/次,静脉滴注,疗程7~10d)。结果随机对照治疗急性呼吸道感染和泌尿生殖系统感染。两组各70例。临床疗效试验药与对照药分别为90.0%和88.6%;细菌清除率分别为88.5%与84.6%。不良反应发生率为11.4%与12.8%。上述结论经统计学检验差异无统计学意义(P>0.05)。开放组临床有效率为88.1%,细菌清除率88.6%,不良反应9.5%。结论头孢哌酮/舒巴坦钠为治疗临床常见的急性呼吸道感染和泌尿生殖系统感染的安全有效的抑酶增效联合制剂。
Objective To evaluate the safety and clinical efficacy of cefoperazone / sulbactam (Rafi). Methods A total of 182 infected patients were enrolled in a randomized controlled and open trial comparing with cefoperazone sulbactam (sulbactam). Medication: Both drugs are (1.5 ~ 3.0g / time 12h / times, intravenous infusion, treatment 7 ~ 10d). Results Randomized controlled trials of acute respiratory infections and genitourinary infections. Two groups of 70 cases each. Clinical efficacy of test drugs and control drugs were 90.0% and 88.6%, respectively; bacterial clearance rates were 88.5% and 84.6%. The incidence of adverse reactions was 11.4% and 12.8%. The above conclusion by statistical test showed no significant difference (P> 0.05). The open clinical effective rate was 88.1%, bacterial clearance rate 88.6%, adverse reactions 9.5%. Conclusion Cefoperazone / sulbactam sodium is a safe and effective synergistic combination for inhibiting acute respiratory infections and urogenital infections in clinical practice.